<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159872</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0870</org_study_id>
    <secondary_id>NCI-2014-01483</secondary_id>
    <nct_id>NCT02159872</nct_id>
  </id_info>
  <brief_title>Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure</brief_title>
  <official_title>A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is learn if omacetaxine can help to control&#xD;
      myelodysplastic syndrome (MDS). The safety of this drug will also be studied.&#xD;
&#xD;
      This is an investigational study. Omacetaxine is FDA approved and commercially available for&#xD;
      the treatment of chronic myelogenous leukemia (CML). It is investigational to use omacetaxine&#xD;
      in patients with MDS. The study doctor can explain how the study drug is designed to work.&#xD;
&#xD;
      Up to 80 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:&#xD;
&#xD;
      Each cycle will be 4-7 weeks, depending on how well the disease responds to the study drug.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will receive omacetaxine as&#xD;
      an injection under your skin 2 times each day, about 12 hours apart, on Days 1-3 of every&#xD;
      28-day study cycle.&#xD;
&#xD;
      You will receive instructions on how to give these injections to yourself. You will be given&#xD;
      a Research Drug Diary to record the drug you take each day. You must bring the Research Drug&#xD;
      Diary and any unused drug with you to each study visit. You will also be told how to properly&#xD;
      store the drugs.&#xD;
&#xD;
      Depending on how the disease responds to the study drugs, the number of days you receive your&#xD;
      injections may stay the same, increase, or decrease. Your doctor will discuss this with you.&#xD;
&#xD;
      During Cycle 1, if the doctor thinks it is needed, you will be given hydroxyurea by mouth to&#xD;
      decrease the risk of side effects. You may ask the study staff for information about how the&#xD;
      drug is given and its risks.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      At the beginning of every cycle, you will have a physical exam before your dose of study&#xD;
      drug.&#xD;
&#xD;
      Every week (+/- 2 days), blood (about 2-3 teaspoons) will be drawn for routine tests. If the&#xD;
      disease appears to get better, this blood will only be drawn every 2-4 weeks while you are&#xD;
      still receiving the study drugs.&#xD;
&#xD;
      If you live far from the clinic, this blood can be drawn at a clinic close to your home, and&#xD;
      the results will be reported to the study doctor.&#xD;
&#xD;
      If the study doctor thinks it is needed, you may have an additional bone marrow aspirate at&#xD;
      any time during the study to check the status of the disease and for cytogenetic testing.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for up to 24 cycles of treatment. You will no longer&#xD;
      be able to take the study drug if the disease gets worse, if intolerable side effects occur,&#xD;
      or if you are unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the follow-up visits.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      You will have follow-up visits at the clinic every 3-6 months for up to 5 years after you&#xD;
      stop taking the study drug. You will be asked about your health and any new drugs you may be&#xD;
      taking. If you cannot come to the clinic, you will be called by the study staff and asked&#xD;
      about your health. These calls should last about 5-10 minutes.&#xD;
&#xD;
      Every 4-8 weeks after your last dose of study drug, blood (about 2-3 teaspoons) will be drawn&#xD;
      for routine tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2015</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2.5 Years</time_frame>
    <description>Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with &lt;/= 5% bone marrow blasts, a peripheral blood granulocyte count &gt;/= (1.0x10^9/L, and a platelet count &gt;/= 100x10^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to &gt;/=100x10^9L.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Omacetaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omacetaxine</intervention_name>
    <description>1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
    <arm_group_label>Omacetaxine</arm_group_label>
    <other_name>Synribo</other_name>
    <other_name>Homoharringtonine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/= 18 years&#xD;
&#xD;
          2. Diagnosis of MDS confirmed within 10 weeks prior to study entry according to WHO&#xD;
             criteria. Patients are either not eligible for or choose not to proceed with a stem&#xD;
             cell transplant.&#xD;
&#xD;
          3. MDS classified as follows: RAEB-1 (5%-9% BM blasts); RAEB-2 (10%-19% BM Blasts); CMML&#xD;
             (5%-19% BM blasts); RAEB-t (20%-29% BM blasts) AND/OR by IPSS: intermediate-1 and high&#xD;
             risk patients.&#xD;
&#xD;
          4. No response, progression, or relapse (according to 2006 IWG criteria) following at&#xD;
             least 4 cycles of either azacitidine or decitabine, which were completed within the&#xD;
             last 2 years - AND/OR - intolerance to azacitidine or decitabine defined as&#xD;
             drug-related &gt;/= grade 3 hepatic or renal toxicity leading to treatment&#xD;
             discontinuation during the preceding 2 years.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;/= 2.&#xD;
&#xD;
          6. Willing to adhere to and comply with all prohibitions and restrictions specified in&#xD;
             the protocol.&#xD;
&#xD;
          7. Patient (or patient's legally authorized representative) must have signed an informed&#xD;
             consent document indicating that the patient understands the purpose of and procedures&#xD;
             required for the study and is willing to participate in the study.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.&#xD;
&#xD;
          2. Active infection not adequately responding to appropriate antibiotics (i.e. ongoing&#xD;
             temperatures of &gt;/= 38 degree Celsius).&#xD;
&#xD;
          3. Total bilirubin &gt;/= 1.5 mg/dL and not related to hemolysis or Gilbert's disease.&#xD;
             Patients with total bilirubin &gt;/= 1.5 mg/dL to 3 mg/dL are eligible if at least 75% of&#xD;
             the bilirubin is indirect.&#xD;
&#xD;
          4. Alanine transaminase (ALT/SGPT) or aspartate transaminase (AST/SGOT) &gt;/= 2.5 x the&#xD;
             upper limit of normal.&#xD;
&#xD;
          5. Serum creatinine &gt; 1.5 mg/dL.&#xD;
&#xD;
          6. Female patients who are pregnant or lactating.&#xD;
&#xD;
          7. Patients with reproductive potential who are unwilling to following contraception&#xD;
             requirements (including condom use for males with sexual partners, and for females:&#xD;
             prescription oral contraceptives [birth control pills], contraceptive injections,&#xD;
             intrauterine devices [IUD], double-barrier method [spermicidal jelly or foam with&#xD;
             condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the&#xD;
             study.&#xD;
&#xD;
          8. Female patients with reproductive potential who do not have a negative urine or blood&#xD;
             beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening.&#xD;
&#xD;
          9. Patients receiving any other concurrent investigational agent or chemotherapy,&#xD;
             radiotherapy, or immunotherapy.&#xD;
&#xD;
         10. Prior hydroxyurea for control of leukocytosis or use of hematopoietic growth factors&#xD;
             (eg, G-CSF, GM-CSF, procrit, aranesp, thrombopoietins) is allowed at any time prior to&#xD;
             or during study if considered to be in the best interest of the patient.&#xD;
&#xD;
         11. Psychiatric illness or social situation that would limit the patient's ability to&#xD;
             comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Jabbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>April 21, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Omacetaxine</keyword>
  <keyword>Synribo</keyword>
  <keyword>Homoharringtonine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Homoharringtonine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02159872/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: May 2015 to September 2018</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Omacetaxine</title>
          <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.&#xD;
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omacetaxine</title>
          <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.&#xD;
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.5" lower_limit="60" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.</description>
        <time_frame>Up to 2.5 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacetaxine</title>
            <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.&#xD;
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0.1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Response</title>
        <description>Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with &lt;/= 5% bone marrow blasts, a peripheral blood granulocyte count &gt;/= (1.0x10^9/L, and a platelet count &gt;/= 100x10^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to &gt;/=100x10^9L.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omacetaxine</title>
            <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.&#xD;
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response</title>
          <description>Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with &lt;/= 5% bone marrow blasts, a peripheral blood granulocyte count &gt;/= (1.0x10^9/L, and a platelet count &gt;/= 100x10^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to &gt;/=100x10^9L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omacetaxine</title>
          <description>Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.&#xD;
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Right Cervical Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea &amp; Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Epigastric Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gingival Infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestianl Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Left Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever, Flu Shot Reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Right Arm Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>RSV Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spasticity (Severe Muscle Spasm)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Subaracnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth Sores</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Forgetfulness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elias Jabbour MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-4764</phone>
      <email>ejabbour@mdaderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

